Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches
Open Access
- 1 January 2013
- journal article
- Published by Frontiers Media SA in Frontiers in Pharmacology
Abstract
The current standard of care for metastatic urothelial carcinoma is cisplatin-based chemotherapy but treatment is generally not curative. Mechanisms of resistance to conventional cytotoxic regimens include tumor cell drug efflux pumps, intracellular anti-oxidants, and enhanced anti-apoptotic signaling. Blockade of signaling pathways with small molecule tyrosine kinase inhibitors has produced dramatic responses in subsets of other cancers. Multiple potential signaling pathway targets are altered in Urothelial carcinoma (UC). Blockade of the PI3K/Akt/mTOR pathway may prove efficacious because 21% have activating PI3K mutations and another 30% have PTEN inactivation (which leads to activation of this pathway). The fibroblast growth factor receptor 3 protein may be overactive in 50–60% and agents which block this pathway are under development. Blockade of multiple other pathways including HER2 and aurora kinase also have potential efficacy. Anti-angiogenic and immunotherapy strategies are also under development in UC and are discussed in this review. Novel therapeutic approaches are needed in UC. We review the various strategies under investigation and discuss how best to evaluate and optimize their efficacy.Keywords
This publication has 68 references indexed in Scilit:
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialThe Lancet Oncology, 2012
- Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perilsEMBO Molecular Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerThe Journal of Pathology, 2007
- Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancerOncogene, 2007
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003